Beam Therapeutics (NASDAQ:BEAM – Get Rating) and AVROBIO (NASDAQ:AVRO – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.
Volatility & Risk
Beam Therapeutics has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for Beam Therapeutics and AVROBIO, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beam Therapeutics | 0 | 2 | 6 | 0 | 2.75 |
| AVROBIO | 0 | 0 | 1 | 0 | 3.00 |
Profitability
This table compares Beam Therapeutics and AVROBIO’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beam Therapeutics | -474.54% | -37.58% | -20.78% |
| AVROBIO | N/A | -82.47% | -66.62% |
Insider & Institutional Ownership
76.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 55.7% of AVROBIO shares are held by institutional investors. 4.0% of Beam Therapeutics shares are held by company insiders. Comparatively, 6.4% of AVROBIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Beam Therapeutics and AVROBIO’s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beam Therapeutics | $60.92 million | 42.20 | -$289.09 million | ($4.13) | -8.60 |
| AVROBIO | N/A | N/A | -$119.13 million | ($2.49) | -0.50 |
AVROBIO has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than AVROBIO, indicating that it is currently the more affordable of the two stocks.
Summary
AVROBIO beats Beam Therapeutics on 7 of the 13 factors compared between the two stocks.
About Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
About AVROBIO
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm’s clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.
Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
